Improving treatment outcomes: tolerability of a fixed-combination clindamycin 1%-benzoyl peroxide 5% hydrating gel as monotherapy or in combination with a retinoid.
Patient adherence to acne therapy is a fundamental element of successful treatment outcomes, which can be increased by the selection of rapidly acting, well-tolerated medications used in simplified regimens. A fixed-combination monotherapy gel containing clindamycin 1% and benzoyl peroxide 5% (C/BPO) has an established safety and efficacy profile through almost a decade of published literature and clinician experience. This unique product may improve a patient's adherence to therapy by providing a well-tolerated and efficacious once-daily monotherapy with multiple mechanisms of action. This article reviews data outlining the enhanced tolerability of the fixed-combination C/BPO gel both alone and when used with a retinoid. The favorable tolerability profile of C/BPO hydrating gel may impart additional benefit to the patient in helping to maintain adherence to treatment.
Eichenfield
Lawrence
L
University of California, San Diego, USA.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D001585:Benzoyl Peroxide / Q000008:administration & dosage* / Q000009:adverse effects; D002981:Clindamycin / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005079:Excipients / Q000737:chemistry; D005782:Gels; D006801:Humans; D055118:Medication Adherence; D012176:Retinoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D005079:Excipients; D005782:Gels; D012176:Retinoids; D002981:Clindamycin; D001585:Benzoyl Peroxide